Skip to content

Screener

Eligibility screening

Testing a Combination of DS-8201a and Olaparib in HER2-Expressing Cancers

Sponsored by National Cancer Institute (NCI)Study detailsClinicalTrials.gov

5 US sites in AZ, FL, MA, MN +1

Before we begin

Who are you filling this out for?

Your answer affects how the questions are phrased.